Update: 05.03.2024
Last week: 8 week 2024 (19.02.2024 - 25.02.2024)
Last full month: January 2024
| Time period | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | |||||||||
| WoW | 6 715 | -6.0% | 11.6% | 0.5 | 15 261 148 | -5.4% | 10.1% | 0.4 | -9.6% |
| MoM | 26 944 | -13.8% | 11.2% | 1.1 | 60 190 108 | -9.5% | 9.7% | 1.2 | -22.4% |
| YTD | 51 700 | 29.6% | 11.1% | 2.3 | 116 025 590 | 62.2% | 9.6% | 2.2 | 2.6% |
| MAT | 352 648 | 34.0% | 9.4% | 1.9 | 701 298 835 | 44.9% | 8.0% | 1.5 | 7.6% |
| BRAINMAX | |||||||||
| WoW | 900 | -2.5% | 100.0% | 0 | 3 244 093 | -3.3% | 100.0% | 0 | -2.5% |
| MoM | 4 282 | -21.7% | 100.0% | 0 | 15 184 484 | -21.8% | 100.0% | 0 | -21.7% |
| YTD | 7 605 | 84.7% | 100.0% | 0 | 27 225 275 | 96.1% | 100.0% | 0 | 84.7% |
| MAT | 50 139 | 250.5% | 100.0% | NA | 174 339 014 | 273.7% | 100.0% | NA | NA |
| GOLDLINE PLUS | |||||||||
| WoW | 14 970 | -13.4% | 42.4% | -1.5 | 47 132 805 | -14.8% | 34.4% | -1.4 | -10.4% |
| MoM | 67 010 | 7.4% | 43.5% | -2.3 | 219 972 521 | 8.7% | 36.1% | -3.2 | 13.2% |
| YTD | 125 015 | 6.1% | 43.4% | 2.2 | 404 325 302 | 14.2% | 35.8% | -1.2 | 0.7% |
| MAT | 876 265 | 22.8% | 45.2% | 2.7 | 2 742 058 257 | 31.1% | 39.4% | 2.4 | 15.6% |
| MIGRENIUM | |||||||||
| WoW | 11 608 | -14.8% | 0.5% | -0.1 | 3 321 349 | -15.8% | 0.7% | -0.1 | -4.8% |
| MoM | 49 774 | 6.2% | 0.5% | 0.1 | 13 094 535 | 21.4% | 0.6% | 0.2 | -12.8% |
| YTD | 95 862 | 2.4% | 0.5% | -0.1 | 26 144 849 | 54.8% | 0.6% | 0.1 | 26.3% |
| MAT | 643 847 | 9.1% | 0.6% | 0 | 131 916 537 | 25.0% | 0.5% | 0 | 9.6% |
| MODELAX-N | |||||||||
| WoW | 30 338 | -2.4% | 23.1% | 0.4 | 12 519 837 | -2.1% | 14.4% | 0.2 | -4.0% |
| MoM | 119 582 | 21.1% | 20.1% | 3.9 | 47 270 565 | 27.9% | 12.0% | 2.8 | -2.4% |
| YTD | 229 097 | 60.9% | 21.3% | 4.7 | 91 950 500 | 99.6% | 12.9% | 3.2 | 25.6% |
| MAT | 1 254 715 | 149.1% | 19.3% | 10.1 | 428 685 812 | 154.4% | 10.9% | 5.7 | 18.7% |
| REDUXIN | |||||||||
| WoW | 11 681 | -10.5% | 33.1% | 0 | 63 884 205 | -10.3% | 46.6% | 0.5 | -10.4% |
| MoM | 52 526 | 24.8% | 34.1% | 3.2 | 284 702 122 | 30.8% | 46.8% | 4.5 | 13.2% |
| YTD | 96 857 | -3.5% | 33.7% | -1.5 | 525 666 596 | 23.8% | 46.5% | 2.2 | 0.7% |
| MAT | 634 311 | 2.9% | 32.7% | -4.1 | 2 974 179 559 | 13.9% | 42.8% | -3.5 | 15.6% |
| REDUXIN FORTE | |||||||||
| WoW | 3 133 | -14.9% | 8.9% | -0.5 | 14 097 547 | -15.3% | 10.3% | -0.5 | -10.4% |
| MoM | 12 983 | 5.2% | 8.4% | -0.6 | 56 969 472 | 5.2% | 9.4% | -1.2 | 13.2% |
| YTD | 25 155 | 9.8% | 8.7% | 0.7 | 112 026 475 | 33.5% | 9.9% | 1.2 | 0.7% |
| MAT | 168 268 | 32.9% | 8.7% | 1.1 | 681 616 279 | 42.5% | 9.8% | 1.3 | 15.6% |
| SALVISAR | |||||||||
| WoW | 7 804 | -11.2% | 1.1% | -0.1 | 2 956 336 | -10.4% | 0.9% | -0.1 | -5.3% |
| MoM | 33 814 | -10.9% | 1.0% | 0 | 11 736 943 | -6.1% | 0.8% | 0 | -10.4% |
| YTD | 63 753 | -25.1% | 1.1% | -0.6 | 22 798 869 | -17.0% | 0.9% | -0.5 | 13.6% |
| MAT | 476 985 | -23.9% | 1.2% | -0.4 | 159 097 242 | -25.1% | 1.0% | -0.4 | 4.6% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 51 700 | 29.6% | 11.1% | 2.3 | 116 025 590 | 62.2% | 9.6% | 2.2 | 2.6% |
| BRAINMAX | 7 605 | 84.7% | 100.0% | 0 | 27 225 275 | 96.1% | 100.0% | 0 | 84.7% |
| GOLDLINE PLUS | 125 015 | 6.1% | 43.4% | 2.2 | 404 325 302 | 14.2% | 35.8% | -1.2 | 0.7% |
| MIGRENIUM | 95 862 | 2.4% | 0.5% | -0.1 | 26 144 849 | 54.8% | 0.6% | 0.1 | 26.3% |
| MODELAX-N | 229 097 | 60.9% | 21.3% | 4.7 | 91 950 500 | 99.6% | 12.9% | 3.2 | 25.6% |
| REDUXIN CAPS | 96 857 | -3.5% | 33.7% | -1.5 | 525 666 596 | 23.8% | 46.5% | 2.2 | 0.7% |
| REDUXIN FORTE | 25 155 | 9.8% | 8.7% | 0.7 | 112 026 475 | 33.5% | 9.9% | 1.2 | 0.7% |
| SALVISAR | 63 753 | -25.1% | 1.1% | -0.6 | 22 798 869 | -17.0% | 0.9% | -0.5 | 13.6% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 352 648 | 34.0% | 9.4% | 1.9 | 701 298 835 | 44.9% | 8.0% | 1.5 | 7.6% |
| BRAINMAX | 50 139 | 250.5% | 100.0% | NA | 174 339 014 | 273.7% | 100.0% | NA | NA |
| GOLDLINE PLUS | 876 265 | 22.8% | 45.2% | 2.7 | 2 742 058 257 | 31.1% | 39.4% | 2.4 | 15.6% |
| MIGRENIUM | 643 847 | 9.1% | 0.6% | 0 | 131 916 537 | 25.0% | 0.5% | 0 | 9.6% |
| MODELAX-N | 1 254 715 | 149.1% | 19.3% | 10.1 | 428 685 812 | 154.4% | 10.9% | 5.7 | 18.7% |
| REDUXIN CAPS | 634 311 | 2.9% | 32.7% | -4.1 | 2 974 179 559 | 13.9% | 42.8% | -3.5 | 15.6% |
| REDUXIN FORTE | 168 268 | 32.9% | 8.7% | 1.1 | 681 616 279 | 42.5% | 9.8% | 1.3 | 15.6% |
| SALVISAR | 476 985 | -23.9% | 1.2% | -0.4 | 159 097 242 | -25.1% | 1.0% | -0.4 | 4.6% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 6 715 | -6.0% | 11.6% | 0.5 | 15 261 148 | -5.4% | 10.1% | 0.4 | -9.6% |
| BRAINMAX | 900 | -2.5% | 100.0% | 0 | 3 244 093 | -3.3% | 100.0% | 0 | -2.5% |
| GOLDLINE PLUS | 14 970 | -13.4% | 42.4% | -1.5 | 47 132 805 | -14.8% | 34.4% | -1.4 | -10.4% |
| MIGRENIUM | 11 608 | -14.8% | 0.5% | -0.1 | 3 321 349 | -15.8% | 0.7% | -0.1 | -4.8% |
| MODELAX-N | 30 338 | -2.4% | 23.1% | 0.4 | 12 519 837 | -2.1% | 14.4% | 0.2 | -4.0% |
| REDUXIN CAPS | 11 681 | -10.5% | 33.1% | 0 | 63 884 205 | -10.3% | 46.6% | 0.5 | -10.4% |
| REDUXIN FORTE | 3 133 | -14.9% | 8.9% | -0.5 | 14 097 547 | -15.3% | 10.3% | -0.5 | -10.4% |
| SALVISAR | 7 804 | -11.2% | 1.1% | -0.1 | 2 956 336 | -10.4% | 0.9% | -0.1 | -5.3% |
| Brand | Volume, packs | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat. Volume Change, % |
|---|---|---|---|---|---|---|---|---|---|
| AMBENE BIO | 26 944 | -13.8% | 11.2% | 1.1 | 60 190 108 | -9.5% | 9.7% | 1.2 | -22.4% |
| BRAINMAX | 4 282 | -21.7% | 100.0% | 0 | 15 184 484 | -21.8% | 100.0% | 0 | -21.7% |
| GOLDLINE PLUS | 67 010 | 7.4% | 43.5% | -2.3 | 219 972 521 | 8.7% | 36.1% | -3.2 | 13.2% |
| MIGRENIUM | 49 774 | 6.2% | 0.5% | 0.1 | 13 094 535 | 21.4% | 0.6% | 0.2 | -12.8% |
| MODELAX-N | 119 582 | 21.1% | 20.1% | 3.9 | 47 270 565 | 27.9% | 12.0% | 2.8 | -2.4% |
| REDUXIN CAPS | 52 526 | 24.8% | 34.1% | 3.2 | 284 702 122 | 30.8% | 46.8% | 4.5 | 13.2% |
| REDUXIN FORTE | 12 983 | 5.2% | 8.4% | -0.6 | 56 969 472 | 5.2% | 9.4% | -1.2 | 13.2% |
| SALVISAR | 33 814 | -10.9% | 1.0% | 0 | 11 736 943 | -6.1% | 0.8% | 0 | -10.4% |
ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе "MS of competitors" в блоке каждого бренда
ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the* last full month* and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection "MS of competitors" in sections for each brand
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "MODELAX-N"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #2"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #4"
## [1] "MODELAX-N SOL RECTAL USE 5 ML #8"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "AMBENE BIO"
## [1] "AMBENE BIO SOL FOR INJ 1 ML #10"
## [1] "AMBENE BIO SOL FOR INJ 2 ML #5"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "MIGRENIUM"
## [1] "MIGRENIUM COATED TABLETS 65 MG+500 MG #20"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "SALVISAR"
## [1] "SALVISAR UNGUENT FOR EXT USE 100 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #1"
## [1] "SALVISAR UNGUENT FOR EXT USE 25 G #2"
## [1] "SALVISAR UNGUENT FOR EXT USE 50 G #1"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN CAPS"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #10"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #30"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #60"
## [1] "REDUXIN CAPS 10 MG+158,5 MG #90"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #10"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #30"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #60"
## [1] "REDUXIN CAPS 15 MG+153,5 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "REDUXIN FORTE"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #30"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #60"
## [1] "REDUXIN FORTE COATED TABLETS 850 MG+15 MG #90"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #30"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #60"
## [1] "REDUXIN FORTE TABS 850 MG + 10 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "GOLDLINE PLUS"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 10 MG+158,5 MG #90"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #10"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #30"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #60"
## [1] "GOLDLINE PLUS CAPS 15 MG+153,5 MG #90"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
## [1] "BRAINMAX"
## [1] "BRAINMAX CAPS 250 MG+250 MG #40"
## [1] "BRAINMAX CAPS 250 MG+250 MG #60"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 2,5 ML #10"
## [1] "BRAINMAX SOL FOR INTRAVEN&INTRAMUSC INJ 100 MG/ML+100 MG/ML 5 ML #10"
[RUS] ОБОЗНАЧЕНИЯ
WoW - Week Over Week - показатели для сравнения результатов текущей и предыдущей недели
MoM - Month Over Month - показатели для сравнения результатов последнего полного месяца и предыдущего полного месяца
YTD - Year to Date - показатели для сравнения результатов за период времени, начинающийся с первого дня текущего календарного года до текущей даты с результатами за сопоставимый период прошлого года
MAT - Moving Annual Total - показатели для сравнения результатов за период 12 месяцев, с датой окончания на последней доступной неделе, с результатами за сопоставимый период прошлого года
MS - Market Share - Доля рынка = (Продажи бренда / Продажи категории)*100%
Change, % = (Продажи бренда за последний период / Продажи бренда за предыдущий период - 1)*100%
Change, p.p. = Доля бренда на рынке за последний период - Доля бренда на рынке за предыдущий период (выражается в процентных пунктах)
Cat. Volume Change, % = (Продажи категории в упаковках за последний период / Продажи категории в упаковках за предыдущий период - 1)*100%
Каждая категория собрана специально для каждого бренда и включает в себя бренд и его конкурентов
Список конкурентов можно найти в разделе "MS of competitors" в блоке каждого бренда
[ENG] ABBREVIATIONS
WoW - Week Over Week - indicators for comparing the results of the current and previous week
MoM - Month Over Month - indicators for comparing the results of the last full month and previous full month
YTD - Year to Date - indicators for comparing the results of the period of time beginning the first day of the current calendar year up to the current date with the results of the comparable period last year
MAT - Moving Annual Total - indicators for comparing the results of the period, being 12 month period ending on the last week with the results of the comparable period last year
MS - Market Share - (Brand Sales / Category Sales)*100%
Change, % = (Brand Sales of the last period / Brand Sales of the previous period - 1)*100%
Change, p.p. = Brand Market Share of the last period - Brand Market Share of the previous period (expressed in percentage points)
Cat. Volume Change, % = (Category Sales in packs of the last period / Category Sales in packs of the previous period - 1)*100%
Each category is created specifically for each brand and includes the brand and its competitors
The list of competitors can be found in the subsection "MS of competitors" in sections for each brand
DATA SOURCES:
DSM: Sales
Palomars: TRPs